CG Oncology, Inc.

Company Overview

CG Oncology, Inc. is a U.S.-based biotechnology company focused on developing and commercializing immunotherapies for bladder cancer. The company operates within the oncology and biopharmaceutical industries, with a primary emphasis on bladder-sparing therapeutic approaches for patients with non–muscle invasive bladder cancer (NMIBC). Its lead product candidate, cretostimogene grenadenorepvec, is an investigational oncolytic immunotherapy designed to selectively replicate in tumor cells and stimulate anti-tumor immune responses. The company’s business model is centered on clinical development, regulatory advancement, and eventual commercialization of proprietary cancer therapeutics.

The company was founded in 2010 and has evolved from an early-stage viral immunotherapy developer into a late-stage clinical biotechnology company with a concentrated focus on urologic oncology. CG Oncology has positioned itself within a specialized segment of the bladder cancer market that includes patients with Bacillus Calmette-Guérin (BCG)-unresponsive disease, an area with significant unmet medical need. Its strategic positioning is supported by a focused pipeline, proprietary viral platform technology, and clinical development efforts targeting both monotherapy and combination treatment opportunities.